



# Balfour Capital Group Merck & Co., Inc.

Merck & Co., Inc., known as MSD outside the U.S. and Canada, is a global healthcare company headquartered in Rahway, New Jersey. The company focuses on the discovery, development, manufacturing, and marketing of prescription medicines, vaccines, biologic therapies, and animal health products. Its pharmaceutical segment addresses various therapeutic areas, including oncology, infectious diseases, cardiometabolic disorders, and vaccines. The animal health division provides veterinary pharmaceuticals and vaccines.

## 1. Top 5 Competitors

Merck's primary competitors in the pharmaceutical industry include:

- Pfizer Inc. (PFE)
- Johnson & Johnson (JNJ)
- Eli Lilly and Company (LLY)
- Novartis AG (NVS)
- Roche Holding AG (RHHBY)

These companies compete with Merck across various therapeutic areas and markets.

## 2. Largest Institutional Shareholders

As of the latest filings, the largest institutional shareholders of Merck are:

- The Vanguard Group, Inc. – approximately 10.03% ownership
- BlackRock Inc. – approximately 6.60% ownership
- State Street Corporation – approximately 4.79% ownership

## 3. Management Team:

Merck's executive leadership includes:

- Robert M. Davis – Chairman and Chief Executive Officer
- Sanat Chattopadhyay – Executive Vice President and President, Merck Manufacturing Division
- Richard R. DeLuca, Jr. – Executive Vice President and President, Merck Animal Health
- Cristal N. Downing – Executive Vice President and Chief Communications & Public Affairs Officer



# Balfour Capital Group Merck & Co., Inc.

## 4. Revenue

In fiscal year 2024, Merck reported total revenues of \$64.17 billion, a 6.74% increase from 2023. The pharmaceutical segment contributed \$57.4 billion, while the animal health segment added \$5.9 billion.

For the first quarter of 2025, Merck reported revenues of \$15.5 billion, a 2% decrease year-over-year, primarily due to a decline in Gardasil vaccine sales in China.

## 5. Institutions with Buy Recommendations:

Several financial institutions have issued buy recommendations for Merck:

- UBS – Buy rating with a price target of \$105.00
- Edward Jones – Buy rating

## 6. Summary of Analyst Sentiment:

Analyst sentiment for Merck is generally positive. As of the latest reports:

- Average Rating: Moderate Buy
- Price Target: The average 12-month price target among analysts is \$111.13.

## 7. Insider Buying and Selling Over the Last 24 Months:

Over the past 24 months, insider trading activity at Merck has been as follows:

- Insider Purchases: Approximately 2,833 shares bought, totaling around \$250,012.25.
- Insider Sales: Approximately 257,682 shares sold, totaling around \$29.84 million.